Akari Therapeutics (NASDAQ:AKTX) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Akari Therapeutics (NASDAQ:AKTX – Get Rating) in a report published on Friday. The firm issued a sell rating on the biopharmaceutical company’s stock. NASDAQ AKTX opened at $1.10 on Friday. Akari Therapeutics has a 52 week low of $1.05 and a 52 week high of $3.20. The stock has […]

Related Keywords

,Akari Therapeutics Company Profile Get Rating ,Omnia Family Wealth ,Wsfs Capital Management ,Citadel Advisors ,Renaissance Technologies ,Millennium Management ,Akari Therapeutics Plc ,Zakari Therapeutics ,Get Rating ,Family Wealth ,Capital Management ,Therapeutics Company Profile ,Nasdaq Aktx ,Aktx ,Medical ,Initiated Coverage ,Stocknews Com ,